Skip to main content

Table 3 Mean change in YMRS, MADRS, BAI and SF-12 at one year by single SGA received

From: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder

Single SGA

Received

LS Mean for

Change from

Baseline to

One Year with Propensity Adjustment

95% Confidence Interval

Pvalue*

YMRS

   

olanzapine (n = 154)

-15.9

-16.7 to -15.2

0.835

risperidone (n = 41)

-15.9

-17.3 to -14.5

 

quetiapine (n = 38)

-15.5

-16.9 to -14.1

 

MADRS

   

olanzapine (n = 154)

-7.5

-8.8 to -6.2

0.552

risperidone (n = 42)

-6.2

-8.7 to -3.7

 

quetiapine (n = 37)

-7.8

-10.4 to -5.3

 

BAI

   

olanzapine (n = 132)

-7.0

-8.4 to -5.6

0.935

risperidone (n = 34)

-6.9

-9.7 to -4.1

 

quetiapine (n = 32)

-6.4

-9.4 to -3.5

 

SF-12 Mental Composite

   

olanzapine (n = 127)

6.3

4.0 to 8.7

 

risperidone (n = 37)

5.0

0.5 to 9.5

0.057

quetiapine (n = 31)

11.9

7.1 to 16.8

 

SF-12 Physical Composite

   

olanzapine (n = 127)

0.6

-1.4 to 2.5

0.077

risperidone (n = 37)

-0.7

-4.4 to 3.0

 

quetiapine (n = 31)

-4.4

-8.4 to -0.5

 
  1. SGA: second generation antipsychotic
  2. YMRS: Young Mania Rating Scale
  3. MADRS: Montgomery Asberg Depression Rating Scale
  4. BAI: Beck Anxiety Inventory
  5. *P value from F-test for any differences among the effects of the three single SGAs